Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Oct 27:5:164.
doi: 10.3389/fendo.2014.00164. eCollection 2014.

Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments

Akira Sasaki  1 , Hiroyuki Nitta  1 , Koki Otsuka  1 , Akira Umemura  1 , Shigeaki Baba  1 , Toru Obuchi  1 , Go Wakabayashi  1
Affiliations
Review

Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments

Akira Sasaki et al. Front Endocrinol (Lausanne). .

Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly common cause of chronic liver disease worldwide. The diagnosis of NASH is challenging as most affected patients are symptom-free and the role of routine screening is not clearly established. Most patients with severe obesity who undergo bariatric surgery have NAFLD, which is associated insulin resistance, type 2 diabetes mellitus (T2DM), hypertension, and obesity-related dyslipidemia. The effective treatment for NAFLD is weight reduction through lifestyle modifications, antiobesity medication, or bariatric surgery. Among these treatments, bariatric surgery is the most reliable method for achieving substantial, sustained weight loss. This procedure is safe when performed by a skilled surgeon, and the benefits include reduced weight, improved quality of life, decreased obesity-related comorbidities, and increased life expectancy. Further research is urgently needed to determine the best use of bariatric surgery with NAFLD patients at high risk of developing liver cirrhosis and its role in modulating complications of NAFLD, such as T2DM and cardiovascular disease. The current evidence suggests that bariatric surgery for patients with severe obesity decreases the grade of steatosis, hepatic inflammation, and fibrosis. However, further long-term studies are required to confirm the true effects before recommending bariatric surgery as a potential treatment for NASH.

Keywords: bariatric surgery; diabetes; laparoscopy; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; obesity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Potential mechanisms or improvement for NAFLD after bariatric surgery.
See this image and copyright information in PMC

References

    1. Patel AA, Torres DM, Harrison SA. Effect of weight loss on nonalcoholic fatty liver disease. J Clin Gastroenterol (2009) 43(10):970–4.10.1097/MCG.0b013e3181b57475 - DOI - PubMed
    1. Kopelman PG. Obesity as a medical problem. Nature (2000) 404(6778):635–43.10.1038/35007508 - DOI - PubMed
    1. Younossi ZM, Reyes MJ, Mishra A, Mehta R, Henry L. Systematic review with meta-analysis: non-alcoholic steatohepatitis – a case for personalized treatment based on pathogenic targets. Aliment Pharmacol Ther (2014) 39(1):3–14.10.1111/apt.12543 - DOI - PubMed
    1. Paredes AH, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Clin Liver Dis (2012) 16(2):397–419.10.1016/j.cld.2012.03.005 - DOI - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and managements of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology (2012) 55(6):2005–23.10.1002/hep.25762 - DOI - PubMed